BiVictriX Therapeutics Plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BVX.L research report →
Companywww.bivictrix.com
BiVictriX Therapeutics Plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia.
- CEO
- Tiffany Jane Thorn
- IPO
- 2021
- Employees
- 17
- HQ
- Macclesfield, GB
Price Chart
Valuation
- Market Cap
- $8.25M
- P/E
- -2.85
- P/S
- 0.00
- P/B
- 2.05
- EV/EBITDA
- -1.83
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -67.92%
- ROIC
- -67.48%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-2,545,000 · -1.92%
- EPS
- $-0.04 · 7.41%
- Op Income
- $-3,025,000
- FCF YoY
- 30.26%
Performance & Tape
- 52W High
- $14.00
- 52W Low
- $10.00
- 50D MA
- $10.91
- 200D MA
- $10.73
- Beta
- -0.73
- Avg Volume
- 198.58K
Get TickerSpark's AI analysis on BVX.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BVX.L Coverage
We haven't published any research on BVX.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BVX.L Report →